February 2018

Evidence suggests AUC-guided vancomycin dosing is a safer method than traditional trough-guided dosing.

Ceftazidime-avibactam is a novel treatment for CRE infections, but reports of resistance are increasing.

A breakthrough message for patients that must be delivered correctly by health care providers. The Undetectable Equals Untransmittable, or U=U, move­ment is a global campaign definitively stating that people living with HIV (PLWH) who have undetectable HIV RNA are unable to transmit HIV. By educating people, the hope is that they will get tested and, if necessary, start and stay on treatment. This message has been endorsed by many organizations, including the US Centers for Disease Control and Prevention and the HIV Medicine Association.

Should patients be screened for emerging infectious diseases based on travel history? Recent studies cast doubt.

An oral alternative for patients requiring broad-spectrum therapy in this era of resistance.

Lingering historical concerns have led to inconsistent practices in antibiotic prophylaxis in this population.

As the ever-changing world of ID continues to evolve, so will Contagion® .

Poignant study adds to the growing body of literature that points toward individualizing duration of therapy for each patient.

One successful model takes an engineering approach to patient safety outcomes focusing on work system improvements.

These pathogens can cause unique challenges for clinicians.

Contagion® Peer Exchange panelists attempt to reach a consensus on the existence of chronic Lyme disease.

A rare metallo-ß-lactamase makes its way into the United States via an 84-year-old patient.

Two recently approved agents offer significant activity against these hard-to-treat conditions.

The lack of a universal flu vaccine and the ease with which borders are crossed means a fast-spreading virus could be devastating.

Treatment-experienced patients still have some good options.

Advances in antiretroviral therapies increase opportunities for patients with HIV to have more successful treatment outcomes.

Bacteriophages are emerging as an alternative to treat highly resistant infections.